Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
420 Leser
Artikel bewerten:
(2)

Newly Released Antiviral Fabric from SQ Group Kills COVID-19 Virus

JINAN, China, Feb. 10, 2021 /PRNewswire/ -- Jinan Shengquan Group Share Holding Co., Ltd. (SQ Group) in collaboration with Hong Kong Nano and Advanced Materials Institute (NAMI) released its latest scientific research result, a newly unveiled antiviral, antibacterial fabric.

Newly Released Antiviral Fabric from SQ Group Kills COVID-19 virus(SARS-CoV-2).

According to the report, the fabric, which is named Nano-VTS, is treated with a special biopolysaccharide material, and able to kill 100% of the COVID-19 virus (SARS-CoV-2) under experimental conditions. This specially designed fabric can provide a long-term and effective prevention against COVID-19 virus infection and is currently being used to mass-produce masks and other personal protective equipment.

Newly Released Antiviral Fabric from SQ Group Kills COVID-19 virus(SARS-CoV-2).

UK VRS test data: 99.99% coronavirus is decreased after 120 minutes' contact with the fabric.

Recently in Jinan, an appraisal meeting was held to discuss the scientific and technological achievements of SQ Group's Nano-VTC antibacterial, antiviral material. Jiang Shicheng, academician from the Chinese Academy of Engineering, Sun Gang, director of the Heilongjiang Animal Disease Prevention and Control Center, and Guan Yuntao, biosafety review expert with the National Health Commission of the People's Republic of China, attended the meeting and concurred that the breakthrough as being a positive step forward in combatting the COVID-19 pandemic both domestically and abroad. Given the absence of such fabrics being used around the world, the attendees concluded that this fabric has extensive application value and recommended its accelerating production and distribution.

SQ Group in collaboration with the Hong Kong Nano and Advanced Materials Institute (NAMI) releases the latest scientific results for their newly unveiled antiviral, antibacterial fabric.

The antiviral effectivity of Nano-VTS has been verified by international and third party institutes. So far, the fabric has passed international standard antiviral and safety tests in US Microbac, British Intertek, Swiss SGS, Guangdong Detection Centre of Microbiology, CNTAC Testing Centre, and German Hohenstein. Patents have been filed around the world to protect its intellectual property.

The newly developed Nano-VTS antibacterial and antiviral fabric effectively kills 3 of the 7 currently known coronaviruses that can infect humans, COVID-19, SARS, and HCoV-229E. Test data from Chinese high-level biosafety laboratories confirm that the fabric can kill 100% of the COVID-19 virus within 60 minutes. The British Virology Research Services (VRS) , an independent third-part testing agency, confirmed the findings that the virus was reduced by 90% within 5 minutes of contact with the fabric and 99.99% after 120 minutes.

According to reports, the biopolysaccharide polymer structure in the fabric can actively adsorb and capture bacteria and viruses by contacting, then kills them through biological activity. As it is the structure of the fabric that make it effective, even after 30 washes, it is still able to kill over 99% of the viruses. This resilience means the Nano-VTS antiviral, antibacterial fabric is ideal for daily use without frequent replacement. Currently, SQ Group masks produced with this fabric have already passed the EU mask standard CWA17553-2020 test and entered the market. In the future, this fabric could also be used in gloves, PPE, hospital bed sheets, and public transportation seat covers.

Experts believe that in terms of epidemic-prevention, anything that can limit the infectivity of surfaces in high-population and high-risk areas will be of great value. SQ Group's Nano-VTS antiviral, antibacterial fabric is a positive achievement in combatting the COVID-19 coronavirus epidemic and saving lives.

For more information, please visit http://e.shengquan.com/index.php

About SQ Group

Jinan Shengquan Group Share Holding Co., Ltd. was founded in 1979 and is located in Shandong province, Zhangqiu City. With 3,600 employees, SQ Group focuses on R&D, and application in biomass materials, and pharmaceuticals. Innovation is at the heart of SQ Group and the company firmly holds respect for labor, knowledge, talent, and creative ideas. Every year, SQ Group invests more than RMB 150 million into research in pursuit of its vision to 'take from nature, serve society, and benefit mankind'.

http://e.shengquan.com/index.php?m=content&c=index&a=show&catid=193&id=238

Photo - https://mma.prnewswire.com/media/1436386/1.jpg
Photo - https://mma.prnewswire.com/media/1436388/2.jpg
Photo - https://mma.prnewswire.com/media/1436385/2.jpg
Photo - https://mma.prnewswire.com/media/1436387/3.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.